COMPOSITIONS AND METHODS FOR INHIBITION OF HIV-1 INFECTION

Abstract: This invention provides a composition which comprises an admixture of two compounds, wherein one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherein the relative mass ratio of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. This invention also provides a method of inhibiting HIV-1 infection of CD4+ cell which comprises contacting the CD4+ cell with an amount of the above composition effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.

Description: COMPOSITIONS AND METHODS FOR INHIBITION OF HIV-1 INFECTION This application is a continuation of U.S. Serial No. 09/493,346, filed January 28, 2000, the contents of which are hereby incorporated by reference. Throughout this application, various publications are referenced within parentheses . Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains. Full bibliographic citations for these references may be found immediately preceding the claims. Background of the Invention Infection of cells by human immunodeficiency virus type 1 (HIV-1) is mediated by the viral envelope (env) glycoprotems gpl20 and gp41, which are expressed as a noncovalent, oligomeric complex on the surface of virus and virally infected cells. HIV-1 entry into target cells proceeds at the cell surface through a cascade of events that include (1) binding of the viral surface glycoprotein gpl20 to cell surface CD4 , which is the primary receptor for HIV-1, (2) env binding to fusion coreceptors such as CCR5 and CXCR4 , and (3) multiple conformational changes in gp41. During fusion, gp41 adopts transient conformations that include a prehairpm fusion intermediate that ultimately folds into a conformation capable of mediating fusion. These events culminate m fusion of the viral and cellular membranes and the subsequent introduction of the viral genome into the target cell. A similar sequence of molecular events is required for infection to spread via fusion of infected and umnfected cells. Each stage of the viral entry process can be targeted for therapeutic intervention. HIV-1 attachment can be inhibited both by agents that bind the viral envelope glycoprotems and by agents that bind human CD4. Notably, HIV-1 attachment can be inhibited by compounds that incorporate the gpl20 -binding domains of human CD4 and molecular mimics thereof [1-7] . Because this interaction between gpl20 and CD4 is essential for virus infection, CD4-based molecules have the potential to target most if not all strains of HIV-1. In addition, viruses have limited ability to develop resistance to such molecules . The determinants for gpl20 binding map to the first extracellular domain (Dl) on CD4 [1] , and the ammo acids critical for binding center on a loop comprising ammo acids 36-47. Potent HIV-1 inhibitory activity has been reproduced a 27-ammo acid peptide that mimics this loop and surrounding structures [7] . A number of recombinant CD4-based molecules have been developed and tested for clinical activity m man. The first of these contained the four extracellular domains (D1-D4) of CD4 but lacked the transmembrane and mtracellular regions. This molecule, termed soluble CD4 (sCD4) , demonstrated excellent tolerability when administered to humans at doses ranging to 10 mg/kg [8,9] . Transient reductions plasma levels of infectious HIV-1 were observed certain patients treated with sCD4. The short half-life of sCD4 m humans (45 minutes following intravenous administration) was identified as one obstacle to usmg this agent for chronic therapy. Second-generation CD -based proteins were developed with increased serum half-l fe. These CD4-ιmmunoglobulm fusion proteins comprised the D1D2 domains of CD4 genetically fused to the hinge CH2 and CH3 regions of human IgG molecules. These divalent proteins derive HIV-1 neutralizing capacity from their CD4 domains and Fc effector functions from the IgG molecule. A CD4-IgGl fusion protein was shown to have excellent tolerability and improved pharmacok etics m Phase I clinical testing [10] . The antiviral evaluations were inconclusive. More recently, a third-generation tetravalent CD4-IgG2 fusion protein was developed that comprises the D1D2 domains of CD4 genetically fused to the heavy and light chain constant regions of human IgG2. This agent binds the HIV-1 envelope glycoprotein gpl20 with nanomolar affinity [5] and may inhibit virus attachment both by receptor blockade and by detaching gpl20 from the virion surface, thereby irreversibly inactivating the virus. In standard PBMC-based neutralization assays, CD4-IgG2 neutralized primary HIV-1 isolates derived from all major subtypes and outlier groups. The CD4-IgG2 concentrations required to achieve a 90% reduction m viral mfectivity, the m vitro IC90, were approximately 15-20 μg/ml [11], concentrations that are readily achievable m vivo. CD4-IgG2 was similarly effective m neutralizing HIV-1 obtained directly from the plasma of seroposit ve donors m an ex vivo assay, indicating that this agent is active against the diverse viral quasispecies that are encountered clinically [12] . CD4-IgG2 also provided protection against infection by primary isolates the hu-PBL-SCID mouse model of HIV-1 infection [13] . Recent analyses have demonstrated that CD4- IgG2 ' s ability to neutralize primary viruses is independent of their coreceptor usage [14] . Compared with mono- or divalent CD4 -based proteins, CD4- IgG2 has consistently demonstrated as much as 100-fold greater potency at inhibiting primary HIV-1 isolates [5,12,14,15] . The heightened potency may derive from CD4- IgG2 ' s ability to bind virions with increased valency/avidity and its steπc juxtaposition of two gpl20 binding sites on each Fab-like arm of the lmmunoglobulm molecule. The larger Fab-like arms of CD4-IgG2 are also more likely to span HIV-1 envelope spikes on the virion. In a variety of preclmical models, CD4-IgG2's antι-HIV-1 activity has been shown to compare favorably with those of the rare human monoclonal antibodies that broadly and potently neutralize primary HIV-1 isolates [5,11,14,15] . In addition, CD4-IgG2 therapy is principle less susceptible to the development of drug-resistant viruses than therapies employing anti-env monoclonal antibodies or portions of the highly mutable HIV-1 envelope glycoprotems . These properties suggest that CD4-IgG2 may have clinical utility as an agent that neutralizes cell-free virus before it has the opportunity to establish new rounds of infection. In addition to treatment, CD4-IgG2 may have utility m preventing infection resulting from occupational, perinatal or other exposure to HIV-1. In Phase I clinical testing, s gle-dose CD4-IgG2 demonstrated excellent pharmacology and tolerability. In addition, measurable antiviral activity was observed by each of two measures. First, a statistically significant acute reduction m plasma HIV RNA was observed following administration of a single 10 mg/kg dose. In addition, sustained reductions plasma levels of infectious HIV were observed m each of two patients tested Taken together, these observations indicate that CD4-IgG2 possesses antiviral activity m humans [16] . In addition to CD4 -based proteins and molecular mimics thereof, HIV-1 attachment can also be inhibited by antibodies and nonpeptidyl molecules. Known inhibitors include (1) anti -env antibodies such as IgGlbl2 and F105 [17,18], (2) antι-CD4 antibodies such as OKT4A, Leu 3a, and humanized versions thereof [19,20], and (3) nonpeptidyl agents that target either gpl20 or CD4 [21] , [22-24] . The latter group of compounds mcludes aurmtricarboxylic acids, polyhydroxycarboxylates, sulfonic acid polymers, and dextran sulfates. Several agents have been identified that block HIV-1 infection by targeting gp41 fusion intermediates. These inhibitors may interact with the fusion intermediates and prevent them from folding mto final fusogenic conformations. The first such agents to be identified comprised synthetic or recombinant peptides corresponding to portions of the gp41 ectodomam predicted to form hydrophobic alpha helices. One such region is present m both the ammo and carboxy segments of the extracellular portion of gp41, and recent crystallographic evidence suggests that these regions interact the presumed fusogenic conformation of gp41 [25,26] . HIV-1 infection can be inhibited by agents that bind to either N- or C-terminal gp41 epitopes that are exposed during fusion. These agents include the gp41-based peptides T-20 (formerly known as DP178) , T-1249, DP107, N34 , C28, and various fusion proteins and analogues thereof [27-33] . Other studies have identified inhibitors that comprise non-natural D-peptides and nonpeptidyl moieties [34,35] . Clinical proof-of-concept for th s class of inhibitors has been provided by T-20, which reduced plasma HIV RNA levels by as much as 2 logs m Phase I/II human clinical testing [36] . The broad antiviral activity demonstrated for this class of mhibitors reflects the high degree of gp41 sequence conservation amongst diverse strains of HIV-1. Recent studies [37] have demonstrated the possibility of raising antibodies against HIV-1 fusion intermediates. This work employed "fusion-competent" HIV vaccine lmmunogens that capture transient fusion intermediates formed upon interaction of gpl20/gp41 with CD4 and fusion coreceptors . The immunogens used m these studies were formalm-flxed cocultures of cells that express HIV-1 gpl20/gp41 and cells that express human CD4 and CCR5 but not CXCR4. The antibodies elicited by tne vaccines demonstrated unprecedented breadth and potency m inhibiting primary HIV-1 isolates regardless of their coreceptor usage, indicating that the antibodies were raised against structures such as gp41 fusion intermediates that are highly conserved and transiently exposed during HIV-1 entry. This class of antibodies does not mclude the antι-gp41 monoclonal antibody known as 2F5, which interacts with an epitope that is constitutively presented on virus particles prior to fusion [38] . Previously, synergistic inhibition of HIV-1 entry has been demonstrated using certain anti-env antibodies used m combination with other anti-env antibodies [39-44], anti- CD4 antibodies [45] , or CD4-based proteins [6] . Similarly, synergies have been observed using antι-CCR5 antibodies used m combination with other antι-CCR5 antibodies, CC- chemok es, or CD4 -based proteins [46] . However, no prior studies have examined the potential synergistic effects of combining inhibitors of gp41 fusion intermediates with inhibitors of other stages of HIV-1 entry. In particular, no studies have examined combinations of inhibitors of gp41 fusion intermediates and HIV-1 attachment. Summary of the Invention This invention provides a composition which comprises an admixture of two compounds, wherein one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of HIV- 1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherem the relative mass ratio of the compounds m the admixture ranges from about 100:1 to about 1:100, the composition bemg effective to inhibit HIV-1 infection of the CD4+ cell. This invention provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the above composition effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell. This invention provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell effective to inhibit HIV-1 infection of the CD4+ cell and an amount of a compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an ep i tope on a gp4 1 fusion intermediate so as to thereby i nhibit HIV-1 infection of the CD4+ cell. Brief Description of the Figures Figure 1 Synergistic inhibition of HIV-1 entry CD4-IgG2 (--■--), T-20 (--•--), and a 25:1 CD4 -IgG2 : T-20 combination (•••A---) were analyzed for inhibition of HIV-1 entry m an env-mediated membrane fusion (RET) assay. Inhibitors were added to a mix of HeLa-EnVjp, FL + and PM1 cells previously labeled with F18 and R18 respectively. Fluorescence RET was measured after 4h of incubation, and percent inhibition was calculated as described [19] . Results are mean values from three independent experiments. The data were analyzed according to the median effect principle described m Equation (1) . The best -fit parameters for K and m are 0.31 μg/ml and 0.73 for CD4- IgG2, 0.017 μg/ml and 0.92 for T-20, and 0.11 μg/ml and 1.0 for their combination. These curves are plotted and indicate a reasonable goodness-of-fit between experiment and theory (r 2 = 0.983, 0.998, and 0.996 for CD4-IgG2, T-20, and their combination, respectively) . To normalize for the differences m potencies of the compounds, separate concentrations scales are used for CD4-IgG2 and the 25:1 CD4-IgG2 :T-20 mixture and for T-20, as indicated. Figure 2 Combination indices for inhibition of HIV-1 entry by combinations of CD4-IgG2 and T-20. CD4-IgG2, T-20 and fixed mass ratios thereof were analyzed m the RET assay for the ability to inhibit env-mediated membrane fusion. The 25:1 (high) combination examined 10 three- fold serial dilutions of 250 μg/ml CD4-IgG2, 10 μg/ml T-20 and their combination. The 25:1 (low) combination examined 10 three- fold serial dilutions of 50 μg/ml CD4-IgG2, 2 μg/ml T-20 and their combmation. The 5:1 combination examined 10 three-fold serial dilutions of 50 μg/ml CD4-IgG2, 2 μg/ml T-20, and their combination. The 1:1 combmation examined 10 three-fold serial dilutions of 10 μg/ml CD4-IgG2, 10 μg/ml T-20 and their combination. Inhibition data from three or more independent assays were averaged prior to analysis. Dose-response curves for the various inhibitors and combinations were fit to Equation (1), which was then rearranged to calculate the inhibitor concentrations required to effect a given percent inhibition. The concentrations of the individual agents m an inhibitory mixture were calculated from their known mass ratios. These values were then used to calculate the Combination Index (CI) according to Equation (2) . CI < 1 indicates synergy, CI = 1 indicates additive effects, and CI> 1 indicates antagonism. Figure 3 Dose reductions observed for synergistic combinations of CD4-IgG2 and T-20. CD4-IgG2, T-20 and a 25:1 fixed mass ratio thereof were tested in the RET assay for the ability to inhibit env-mediated membrane fusion. Inhibition data from s x independent assays were averaged. K and m were determmed by curve- fitting the dose-response curves, and Equation (1) was rearranged to allow calculation of c for a given f for the single agents and their combination. Dose Reduction is the ratio of the inhibitor concentrations required to achieve a given degree of inhibition when the inhibitor is used alone v. m a synergistic combination. Detailed Description of the Invention The plasmids CD4-IgG2-HC-pRcCMV and CD4-kLC-pRcCMV were deposited pursuant to, and m satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms (the "Budapest Treaty" ) for the Purposes of Patent Procedure with the American Type Culture Collection (ATCC) , 12301 Parklawn Drive, Rockville, MD 20852 under ATCC Accession Nos. 75193 and 75194, respectively. The plasmids were deposited with ATCC on Jan. 30, 1992. The plasmid designated pMA243 was similarly deposited m accordance with the Budapest Treaty with ATCC under Accession No. 75626 on December 16, 1993. As used herein, the following standard abbreviations are used throughout the specification to indicate specific ammo acids : A=ala=alanme R=arg=argmme N=asn=asparagme D=asp=aspartιc acid C=cys=cysteme Q=gln=glutamme E=glu=glutamιc acid G=gly=glycme H=hιs=hιstιdme I = ιle = ιsoleucme L=leu=leucme K=lys = lysme M=met=methιonme F=phe=phenylalanme P=pro=prolme S = ser=serme T=thr=threonme =trp= tryptophan Y=tyr=tyrosme V=val=valme This invention provides a composition which comprises an admixture of two compounds, wherein one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of I-IIV- 1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherein the relative mass ratio of the compounds in the admixture ranges from about 1 0:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. As used herein, "HIV-1" means the human immunodeficiency virus type-1. HIV-1 includes but is not limited to extracellular virus particles and the forms of KIV-1 associated with HIV-1 infected cells. HIV-1 JR _ F is a strain that was originally isolated at autopsy from the brain tissue of an AIDS patient [47] . The virus was co-cultured with lectin-stimulated normal human peripheral blood mononuclear cells. The virus has been cloned and the DNA sequences of its envelope glycoproteins are known (Genbank Accession #U63632) . In terms of sensitivity to inhibitors of viral entry, HIV-l^.^. is known to be highly representative of primary HIV-1 isolates [11,14,15,48-50] . As used herein, "gp41 fusion intermediates" includes structures, conformations, and oligomeric states that are preferentially and transiently presented or exposed o the HIV-1 envelope glycoprotein gp41 during the process of HIV- 1 env-mediated membrane fusion. These intermediates may form upon interaction of HIV-1 with cellular receptors or may be present m partially or fully occluded states on HIV-1 prior to its interaction with cellular receptors. "gp41 fusion intermediates" do not mclude fusogenic gp41 conformations that cannot provide targets for therapeutic intervention . The gp41 fusion intermediates may contain multiple epitopes that are transiently exposed during fusion and can provide targets for therapeutic intervention. As used herein, an "N-termmal gp41 epitope" may comprise all or portions of the sequences from ammo acid A541 to Q590. As used herein, a "C-termmal gp41 epitope" may comprise all or portions of the sequences from ammo acid 628 to L663. These epitopes have the potential to form coiled-coils of interacting alpha helical segments by virtue of heptad (sequence of seven ammo acids) repeats containing hydrophobic ammo acids at positions 1 and 4 of the heptad. The ammo acid numbering system is for the HxB2 isolate of HIV-1 (Genbank Protein Accession No. AAB50262) . Because of the sequence variability of HIV-1 envelope proteins, the composition, size and precise location of such sequences may be different for different viral isolates. The gp41 fusion intermediates may also present other linear or conformational epitopes that are transiently expressed during HIV-1 entry. An inhibitor may target multiple epitopes present on gp41 fusion intermediates. Alternatively, separate inhibitors may be used m combmation to target one or more epitopes present on gp41 fusion intermediates. As used herein, "fusogenic" means capable of mediating membrane fusion. As used herein, "HIV-1 fusion coreceptor" means a cellular receptor that mediates fusion between the target cell expressing the receptor and HIV-1 or an HIV-1 envelope glycoprotein" cell. HIV-1 fusion co-receptors include but are not limited to CCR5 , CXCR4 and other chemokme receptors. As used herein, "fusion" means the joining or union of the lipid bilayer membranes found on mammalian cells or viruses such as HIV-1. This process is distinguished from the attachment of HIV-1 to a target cell. Attachment is mediated by the binding of the HIV-1 exterior glycoprotein to the human CD4 receptor, which is not a fusion co-receptor. As used herein, "retards" means that the amount is reduced. As used herein, "attachment" means the process that is mediated by the binding of the HIV-1 envelope glycoprotein to the human CD4 receptor, which is not a fusion co- receptor. As used herein, "CD4" means the mature, native, membrane-bound CD4 protein comprising a cytoplasmic domain, a hydrophobic transmembrane domain, and an extracellular domain which binds to the HIV-1 gpl20 envelope glycoprotein . As used herein, "epitope" means a portion of a molecule or molecules that form a surface for binding antibodies or other compounds. The epitope may comprise contiguous or noncontiguous ammo acids, carbohydrate or other nonpeptidyl moities or oligomer-specifIC surfaces. The compounds of the subject invention have shown to demonstrate a synergistic effect. As used herein, "synergistic" means that the combined effect of the compounds when used m combination is greater than their additive effects when used individually. In one embodiment of the above composition, the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a CD4 -based protein. As used herein, "CD4 -based protein" means any protein comprising at least one sequence of ammo acid residues corresponding to that portion of CD4 which is required for CD4 to form a complex with the HIV-1 gpl20 envelope glycoprotein. In one embodiment, the CD4 -based protein is a CD4 - lmmunoglobulm fusion protein. In one embodiment, the CD4 - lmmunoglobulm fusion protein is CD4-IgG2, which is a heterotetrameπc CD4 -human IgG2 fusion protein. In one embodiment, the CD4-IgG2 comprises two heavy chains and two lights chains, wherem the heavy chains are encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC Accession No. 75193) and the light chains are encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC Accession No . 75194 ) . In one embodiment of the above composition, the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a protein, the amino acid sequence of which comprises that of a protein found in HIV-1 as an envelope glycoprotein. In one embodiment, the protein binds to an epitope of CD4 on the surface of the CD4+ cell. The envelope glycoprotein includes but is not limited to gpl20, gpl60, or gpl40. In one embodiment of the above composition, the compound which retards the attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is an antibody or portion of an antibody. In one embodiment, the antibody is a monoclonal antibody. The antibody of the subject invention may be a human, humanized or chimeric antibody. In one embodiment, the portion of the antibody is a Fab fragment of the antibody. In one embodiment, the portion of the antibody comprises the variable domain of the antibody. In one embodiment, the portion of the antibody comprises a CDR portion of the antibody. The monoclonal antibody of the subject invention includes but is not limited to an IgG, IgM, IgD, IgA, or IgE monoclonal antibody. As used herein, "antibody" means an immunoglobulin molecule comprising two heavy chains and two light chains and which recognizes an antigen. The lmmunoglobulm molecule may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG ana IgM. IgG subclasses are also well known to those the art and mclude but are not limited to human IgGl, IgG2, IgG3 and IgG4. It includes, by way of example, both naturally occurring and non-naturally occurring antibodies. Specifically, "antibody" includes polyclonal and monoclonal antibodies, and monovalent and divalent fragments thereof. Furthermore, "antibody" includes chimeric antibodies, wholly synthetic antibodies, single chain antibodies, and fragments thereof. The antibody may be a human or nonhuman antibody. A nonhuman antibody may be humanized by recombinant methods to reduce its immunogenicity m man. Methods for humanizing antibodies are known to those skilled m the art. In one embodiment, the monoclonal antibody binds to an HIV- 1 envelope glycoprotein. The HIV-1 envelope glycoprotein includes but is not limited to gpl20 and gpl60. In one embodiment, the HIV-1 envelope glycoprotein is gpl20 and the monoclonal antibody which binds to gpl20 is IgGlbl2 or F105. IgGlbl2 is listed as item #2640 m the NIH AIDS Research and Reference Reagent Program Catalog. F105 is listed as item #857 the NIH AIDS Research and Reference Reagent Program Catalog. In one embodiment, the antibody binds to an epitope of CD4 on the surface of the CD4+ cell. In one embodiment, the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4 + cell is a peptide. In one embodiment, the compound which retards attachment of HIV-1 to the CD4+ cell is a nonpeptidyl agent. As used herein, "nonpeptidyl" means that the agent does not consist m its entirety of a linear sequence of ammo acids linked by peptide bonds. A nonpeptidyl agent may, however, contain one or more peptide bonds . In one embodiment of the above composition, the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is an antibody. In one embodiment, the antibody is a monoclonal antibody. In another embodiment, the antibody is a polyclonal antibody. In one embodiment of the above composition, the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a peptide. In one embodiment, the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV- 1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a fusion protein which comprises a peptide selected from the group consisting of T-20 (SEQ ID NO: 1) , DP107 (SEQ ID NO: 2) , N34 (SEQ ID NO: 3), C28 (SEQ ID NO: 4), and N34 (L6) C28 (SEQ ID NO: 5). As used herein, "T-20" and "DP178" are used interchangeably to denote a peptide having the following ammo acid sequence : YTSLIHSLIEESQNQQEKNEQELLELDK ASLWN F (SEQ ID NO : 1 ) and as described [29,32] . DP107 has the following ammo acid sequence: NNLLRAIEAQQHLLQLTV GIKQLQARILAVERYLKDQ (SEQ ID NO : 2 ) N34 has the following amino acid sequence: SGIVQQQNNLLRAIEAQQHLLQLTV GIKQLQAR (SEQ ID NO : 3 ) C28 has the following amino acid sequence: WMEWDREINNYTSLIHSLIEESQNQQEK (SEQ ID NO : 4 ) N34(L6)C28 has the following amino acid sequence: SGIVQQQNNLLRAIEAQQHLLQLTV GIKQLQARSGGRGG MEWDREINNYTSLIHS LIEESQNQQEK (SEQ ID NO: 5) In one embodiment of the above composition, the peptide is selected from the group consisting of T-20 (SEQ ID NO: 1), DP107 (SEQ ID NO: 2), N34 (SEQ ID NO: 3), C28 (SEQ IE NO: 4), and N34 (L6)C28 (SEQ ID NO: 5). In one embodiment of the above composition, the peptide is T-20 (SEQ ID NO: 1) . In one embodiment of the above composition, the peptide is a mutant peptide which (1) consists of amino acids having a sequence identical to that of a wildtype peptide selected from the group consisting of T-20 (SEQ ID NC : 1), DF-107 (SEQ ID NO: 2), N34 (SEQ ID NO: 3), C28 (SEQ ID NO: 4), and N34(L6)C28 (SEQ ID NO: 5), except for an addition cf at least one glycine residue to a 5 ' end of the peptide, to a 3' end of the peptide, or to both ends of the peptide and (2) retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate. In one embodiment, the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV- 1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a non-peptidyl agent. In one embodiment of the above composition, the relative mass ratio of each such compound in the admixture ranges from about 25:1 to about 1:1. In one embodiment of the above composition, the mass ratio is about 25:1 In one embodiment of the above composition, the mass ratio is about 5:1. In one embodiment of the above composition, the mass ratio is about 1:1. In one embodiment of the above composition, the composition is admixed with a carrier. The carrier of the subject invention may be an aerosol, intravenous, oral or topical carrier. Pharmaceutically acceptable carriers are well known to those skilled in the art. Such pharmaceutically acceptable carriers may include but are not limited to aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers , electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like. This invention provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4 + cell with an amount of the above composition effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell. In one embodiment, the CD4+ cell is present a subject and the contacting is effected by administering the composition to the subject. As used herein, "subject" includes any animal or artificially modified animal capable of becoming HIV- mfected. Artificially modified animals include, but are not limited to, SCID mice with human immune systems. The animals include but are not limited to mice, rats, dogs, cats, guinea pigs, ferrets, rabbits, and primates. In the preferred embodiment, the subject is a human. In one embodiment, the effective amount of the composition comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight of the subject. As used herein, "administering" may be effected or performed using any of the methods known to one skilled the art, which includes mtralesional , mtraperitoneal , intramuscular, subcutaneous, intravenous, liposome mediated delivery, transmucosal , intestinal, topical, nasal, oral, anal, ocular or otic delivery. The compounds may be administered separately (e.g., by different routes of administration, sites of injection, or dosing schedules) so as to combine m synergistically effective amounts the subj ect . The dose of the composition of the invention will vary depending on the subject and upon the particular route of administration used. Dosages can range from 0.1 to 100,000 μg/kg. Based upon the composition, the dose can be delivered continuously, such as by continuous pump, or at periodic intervals. For example, on one or more separate occasions. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled m the art. As used herein, "effective dose" means an amount m sufficient quantities to either treat the subject or prevent the subject from becoming infected with HIV-1. A person of ordinary skill m the art can perform simple titration experiments to determine what amount is required to treat the subject. This invention provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell effective to inhibit HIV-1 infection of the CD4+ cell and an amount of a compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate so as to thereby mhibit HIV-1 infection of the CD4+ cell. In one embodiment, the CD4+ cell is present m a subject and the contacting is effected by administering the compounds to the s oject. In one embodiment, the compounds are administered to the subject simultaneously. In another embodiment, the compounds are administered to the subject at different times. In one embodiment, the compounds are administered to the subject by different routes of administration. The subject invention has various applications which includes HIV treatment such as treating a subject who has become afflicted with HIV. As used herein, "afflicted with HIV-1" means that the subject has at least one cell which has been infected by HIV-1. As used herein, "treating" means either slowing, stopping or reversing the progression of an HIV-1 disorder. In the preferred embodiment, "treating" means reversing the progression to the point of eliminating the disorder. As used herein, "treating" also means the reduction of the number of viral infections, reduction of the number of infectious viral particles, reduction of the number of virally infected cells, or the amelioration of symptoms associated with HIV-1. Another application of the subject invention is to prevent a subject from contracting HIV. As used herein, "contracting HIV-1" means becoming infected with HIV-1, whose genetic information replicates m and/or incorporates mto the host cells. Another application of the subject invention is to treat a subject who has become infected with HIV-1. As used herein, "HIV-1 infection" means the introduction of HIV-1 genetic information mto a target cell, such as by fusion of the target cell membrane with HIV-1 or an HIV-1 envelope glycoprotein* cell. The target cell may be a bodily cell of a subject. In the preferred embodiment, the target cell is a bodily cell from a human subject. Another application of the subject invention is to inhibit HIV-1 infection. As used herein, "inhibiting HIV-1 infection" means reducing the amount of HIV-1 genetic information introduced mto a target cell population as compared to the amount that would be introduced without said composition. This invention will be better understood from the Experimental Details that follow. However, one skilled m the art will readily appreciate that the specific methods and results discussed are merely illustrative of the invention as described more fully the claims that follow thereafter. Experimental Details A. Materials and Methods 1) Reagents Purified recombinant CD4-IgG2 protein was produced by Progenies Pharmaceuticals, Inc. from plasmids CD4-IgG2-HC- pRcCMV and CD4-kLC-pRcCMV (ATCC Accession Nos. 75193 and 75194, respectively) as described [5] . HeLa-env cells were prepared by transfectmg HeLa cells (ATCC Catalog # CCL-2) with HIV-1 gpl20/gp41 env-expressmg plasmid pMA243 as described [51] . PM1 cells are available from the National Institutes of Health AIDS Reagent Program (Catalog #3038) . The T-20 peptide was synthesized using standard solid-phase Fmoc chemistry and purified and characterized as described [31,32] . 2) Inhibition of HIV-1 env-mediated membrane fusion HIV-1 envelope-mediated fusion between HeLa-Env JR FL and PM1 cells was detected using a Resonance Energy Transfer (RET) assay. Equal numbers (2x104) of fluorescem octadecyl ester (F18) -labeled envelope-expressing cells and octadecyl rhodamme (R18) -labeled PM1 cells were plated m 96-well plates m 15% fetal calf serum m phosphate buffered saline and incubated for 4h at 37 (C m the presence of varying concentrations of CD4-IgG2, T-20 or combinations thereof. Fluorescence RET was measured with a Cytofluor plate-reader (PerSeptive Biosystems) and % RET was determined as previously described [19] . 3 ) Quantitative analysis of the synergistic, additive or antagonistic effects of combining the agents HIV-1 inhibition data were analyzed according to the Combination Index method of Chou and Talay [52,53] . The data are modeled according to the median-effect principle, which can be written f = 1/ [1 + (K/c) m ] (1) where f is the fraction affected/mhibited, c is concentration, K is the concentration of agent required to produce the median effect, and m is an empirical coefficient describing the shape of the dose-response curve. Equation (1) is a generalized form of the equations describing Michaelis-Menton enzyme kinetics, Langmuir adsorption isotherms, and Henderson-Hasselbalch lonization equilibria, for which m = 1 m all cases. In the present case, K is equal to the IC 50 value. K and m are determined by curve-fitting the dose-response curves. After the best-fit parameters for K and m are obtained for the experimental agents and their combination, Equation (1) is rearranged to allow for calculation of c for a given f. The resulting table of values (e.g., Figure X) is used to calculate the Combination Index (CI) using the equation CI = c lm / c 1 + c 2m / c 2 + c ,_c 2m / c 1 c 2 ( 2 ) where c λ = concentration of compound 1 when used alone c 2 = concentration of compound 2 when used alone c lra = concentration of compound 1 in the mixture c 2m = concentration of compound 2 in the mixture All concentrations are those required to achieve a given degree of inhibition. Equation (2) is used when the molecules are mutually nonexclusive, i.e., have different sites of action. Since this is the likely scenario for inhibitors of HIV-1 attachment and gp41 fusion intermediates, Equation (2) was used for all Combination Index calculations. Mutually nonexclusive calculations provide a more conservative estimate of the degree of synergy that mutually exclusive calculations, for which the c lm c 2m /c 1 c 2 term is dropped. CI < 1 indicates synergy, CI = 1 indicates purely additive effects, and CI > 1 indicates antagonism. In general, CI values are most relevant at the higher levels of inhibition that are required to achieve a measurable clinical benefit. B. Results and Discussion Combinations of inhibitors of HIV-1 attachment and gp41 fusion intermediates were first tested for the ability to hibit HIV-1 env-mediated membrane fusion m the RET assay. This assay has proven to be a highly successful model of the HIV-1 entry process. In this assay, env- dependent coreceptor usage patterns and cellular tropisms of the parental viruses are accurately reproduced [19] . Indeed, the assay was instrumental m demonstrating that CCR5 functions as a requisite fusion coreceptor and acts at the level of viral entry [54] . The fusion assay and infectious virus are similarly sensitive to inhibition by metal chelators and agents that target the full complement of viral and cellular receptors [19,46,55] . Dose-response curves were obtained for the agents used individually and m combination m both assays. Data were analyzed using the median effect principle [52,53]. The concentrations of single-agents or their mixtures required to produce a given effect were quantitatively compared m a term known as the Combination Index (CI) . CI > 1 indicates antagonism, CI = 1 indicates a purely additive effect, and CI < 1 indicates a synergistic effect wherem the presence of one agent enhances the effect of another. Combinations of CD4-IgG2 and T-20 were observed to be potently synergistic m inhibiting env-mediated membrane fusion. Figure 1 illustrates representative dose-response curves obtained m the membrane fusion assay for CD4-IgG2, T-20, and combinations of the two. The curve for the combination is highly displaced towards lower inhibitor concentrations and provides qualitative evidence that CD4- IgG2 and T-20 act m a synergistic manner. To quantitatively calculate the degree of synergy observed between CD4-IgG2 and T-20, we analyzed the dose-response curves according to the Combination Index method [52,53] . The analysis included data obtained at 25:1, 5:1, and 1:1 CD4-IgG2 :T-20 mass ratios. At the 25:1 mass ratio, both high (0-250 μg/ml CD4-IgG2 and 0-10 μg/ml T-20) and low (0- 50 μg/ml CD4-IgG2 and 0-2 μg/ml T-20) concentration ranges were evaluated. As indicated m Figure 2, potent synergies were observed over these broad ranges of inhibitor ratios and concentrations, with CI values as low as 0.20 under optimal conditions. This degree of synergy is remarkable since CI values of 0.2 are rarely observed for combinations involving antι-HIV-1 antibodies [41-44] , reverse transcπptase inhibitors [56] , or protease inhibitors [57] . The observed synergies indicate that HIV-1 attachment and formation of gp41 fusion intermediates are mter-dependent steps. One possibility is that attachment inhibitors, when used at suboptimal concentrations, may slow but not abrogate the binding of gpl20 to CD4. In this case, gp41 fusion intermediates may be formed and persist on the virus (or infected cell) for longer periods of time at levels below that required for membrane fusion and thus provide better targets for inhibitory agents. The observed synergies translate mto significant reductions m the amounts of CD4-IgG2 and T-20 needed for inhibition. These reductions are illustrated m Figure 3 for CD4-IgG2 and T-20 used in a 25:1 mass ratio. By way of example, inhibition of viral entry by 95% requires 0.21 μg/ml of T-20 used alone, 19 μg/ml of CD4-IgG2 used alone and 1.14 μg/ml of a combination containing 0.044 μg/ml of T-20 and 1.1 μg/ml of CD4-IgG2. The combination reduces the respective doses of T-20 and CD4-IgG2 by 5- and 17-fold, respectively. Still greater dose reductions are observed at higher levels of inhibition. REFERENCES 1. Arthos J, Deen KC, Chaikin MA et al . Identification of the residues in human CD4 critical for the binding of HIV. Cell 1989; 57:469-481. 2. Clapham PR., Weber JN. , Whitby D. et al . Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 1989; 337:368-370. 3. Deen KC . , McDougal JS . , Inacker R. et al . A soluble form of CD4 (T4) protein inhibits AIDS virus infection. Nature 1988; 331:82-84. 4. Capon DJ, Chamow SM, Mordenti J et al . Designing CD4 immunoadhesins for AIDS therapy. Nature 1989; 337:525- 531. 5. Allaway GP, Davis-Bruno KL, Beaudry GA et al . Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Research and Human Retroviruses 1995; 11:533-539. 6. Allaway GP, Ryder AM, Beaudry GA, Maddon PJ . Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4 -based molecules m combination with antibodies to gpl20 or gp41. AIDS Research &_ Human Retroviruses 1993; 9:581-587. 7. Vita C, DraKopoulou E, Vizzavona J et al . Rational engineering of a mmiprotem that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 1999; 96:13091- 13096. 8. Schacker T., Coombs RW., Collier AC. et al . The effects of high-dose recombinant soluble CD4 on human immunodeficiency virus type 1 viremia. Journal of Infectious Diseases 1994; 169:37-40. 9. Schacker T, Collier AC, Coombs R et al . Phase I study of high-dose, intravenous rsCD4 m subjects with advanced HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:145-152. 10. Collier AC, Coombs RW, Katzenstem D et al . Safety, pharmacokmetics, and antiviral response of CD4- lmmunoglobul G by intravenous bolus m AIDS and AIDS-related complex. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:150-156. 11. Trkola A., Pomales AP., Yuan H. et al . Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG2. Journal of Virology 1995; 69:6609-6617. 12. Gaudu M-C, Allaway GP . , Maddon PJ., Barbas CF3 , Burton DR, Koup RA . Effective ex vivo neutralization of plasma HIV-1 by recombinant lmmunoglobul molecules. Journal of Virology 1996; 70:2586-2592. 13. Gaudu M-C, Allaway GP, Olson WC, Weir R., Maddon PJ, Koup RA. CD4 -lmmunoglobulm G2 protects Hu-PBL- SCID mice against challenge by primary human immunodeficiency virus type 1 isolates. Journal of Virology 1998; 72:3475-3478. 14. Trkola A, Ketas T, KewalRamani VN et al . Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4- based reagents is independent of coreceptor usage. J Virol 1998; 72:1876-1885. 15. Fouts TR, Bmley JM, Trkola A, Robinson JE, Moore JP . Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. Journal of Virology 1997; 71:2779-2785. 16. Jacobson J, Lowy I, Trkola A et al . Results of a Rhase I Trial of Smgle-Dose PRO 542, a Novel Inhibitor of HIV Entry. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999; 14. 17. Burton DR, Pyati J, Koduπ R et al . Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266 :1024-1027. 18 . Posner MR . , Cavacmi LA . , Ernes CL . , Power J . , Byrn R . N eutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gpl2C. Journal of Acquired Immune Deficiency Syndromes 19S3; 6:7-14. 19. Litwm V, Nagashima KA, Ryder AM et al . Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer. Journal of Virology 1996; 70:6437-6441. 20. Poignard P, Peng T, Sabbe R, Newman V, , Mosier DE, Burton DR. Blocking of HIV-1 Co-receptor CCR5 in the hu-PBL-SCID Mouse Leads to a Co-receptcr Switch. 6th Conference on Retroviruses and Opportunistic Infections 1999; 21. Cushman M, Wang PL, Chang SH et al . Preparation and anti-HIV activities of aurintπcarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weigh . J Med Chem 1991; 34:329-337. 22. Mohan P, Schols D, Baba M, De Clercq E. Sulfonic acid polymers as a new class of human immunodeficiency virus inhibitors. Antiviral Res 1992; 16:139-150. 23. Schols D, Pauwels R, Desmyter J, De Clercq E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gpl20 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology 1990; 175:556-561. 24. Schols D, Wutzler P, Klockmg R, Helbig B, De Clercq E. Selective inhibitory activity of polyhydroxycarboxylates derived from phenolic compounds against human immunodeficiency virus replication. J Acquir Immune Defic Syndr 1991; 4:677- 685. 25. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomam from HIV-1 gp41. Nature 1997; 387:426-430. 26. Chan DC, Fass D, Berger JM, Kim PS. Core Structure of gp41 from the HIV Envelope Glycoprotein. Cell 1997; 89:263-273. 27. Ji H, Shu W, Burling FT, Jiang S, Lu M. Inhibition of human immunodeficiency virus type 1 mfectivity by the gp41 core: role of a conserved hydrophobic cavity m membrane fusion. Journal of Virology 1999; 73:8578- 8586. 28. Jiang S, Lm K, Strick N, Neurath AR. HIV-1 inhibition by a peptide. Nature 1993; 365:113. 29. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus- mediated cell-cell fusion. AIDS Res Hum Retroviruses 1993; 9:1051-1053. 30. Wild C, Greenwell T, Shugars D, Rimsky-Clarke L, Matthews T. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucme zipper structure. AIDS Res Hum Retroviruses 1995; 11:323-325. 31. Wild C, Oas T, McDanal C, Bolognesi D, Matthews T. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 1992; 89:10537-10541. 32. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91:9770-9774. 33. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity m the coiled coil of HIV type 1 gp41 is an attractive drug target . Proc Natl Acad Sci U S A 1998; 95:15613-15617. 34. Ferrer M, Kapoor TM, Strassmaier T et al . Selection of gp41-medιated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements. Nat Struct Biol 1999; 6:953-960. 35. Eckert DM, Malashkevich VN, Hong LH, Carr PA, Kim PS. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 1999; 99:103-115. 36. Kilby JM, Hopkins S, Venetta TM et al . Potent suppression of HIV-1 replication m humans by T-20, a peptide inhibitor of gp41-medιated virus entry. Nat Med 1998; 4:1302-1307. 37. LaCasse RA, Follis KE, Trahey M, Scarborough JD, Littman DR, Nunberg JH. Fusion- competent vaccines: broad neutralization of primary isolates of HIV. Science 1999; 283:357-362. 38. Neurath AR, Strick N, Lm K, Jiang S. Multifaceted consequences of antι-gp41 monoclonal antibody 2F5 binding to HIV type 1 viπons . AIDS Res Hum Retroviruses 1995; 11:687-696. 39. Thali M, Furman C, Wahren B et al . Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gpl20 envelope glycoprotein. J Acquir Immune Defic Syndr 1992; 5:591-599. 40. Tilley SA, Honnen WJ, Racho ME, Chou TC, Pinter A. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and tne CD4- binding site of gpl20. AIDS Res Hum Retroviruses 1992; 8 :461-467. 41. Laal S, Burda S, Gorny MK, Karwowska S, Buchbmder A, Zolla-Pazner S. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. Journal of Virology 1994; 68 :4001-4008. 42. Vijh-Warπer S, Pinter A, Honnen WJ, Tilley SA. Synergistic neutralization of human immunodef ciency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gpl20 m combination with monoclonal antibodies against the V3 loop and tne CD4- binding site. Journal of Virology 1996; 70:4466-4473. 43. Li A, Baba TW, Sodroski J et al . Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hypeπmmune globulins. AIDS Res Hum Retroviruses 1997; 13:647-656. 44. Li A, Katmger H, Posner MR et al . Synergistic neutralization of simian-human immunodeficiency virus SHIV- vpu-i- by triple and quadruple comoinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 lmmunoglobul s . Journal of Virology 1998; 72:3235-3240. 45 Burkly L, Mulrey N, Blumenthal R, Dimitrov DS . Synergistic inhibition of human immunodef ciency virus type 1 envelope glycoprotem-mediated cell fusion and infection by an antibody to CD4 domain 2 m combination with antι-gpl20 antibodies. Journal of Virology 1995; 69:4267-4273. 46. Olson WC, Rabut GE , Nagashima KA et al . Differential inhibition of human immunodeficiency virus type 1 fusion, gpl20 binding, and CC-chemokme activity by monoclonal antibodies to CCR5. J Virol 1999; 73:4145- 4155. 47. O'Brien WA. , Koyanagi Y., Namazie A. et al . HIV-1 tropism for mononuclear phagocytes can be determined by regions of gpl20 outside the CD4 -binding domain. Nature 1990; 348:69-73. 48. Trkola A, Matthews J, Gordon C, Ketas T, Moore JP . A cell line-based neutralization assay for primary human immunodeficiency virus type 1 isolates that use either the CCR5 or the CXCR4 coreceptor. J Virol 1999; 73:8966-8974. 49. Fouts TR, Trkola A, Fung MS, Moore JP . Interactions of polyclonal and monoclonal anti -glycoprotein 120 antibodies with oligomeric glycoprotein 120- glycoprotem 41 complexes of a primary HIV type 1 isolate: relationship to neutralization. AIDS Res Hum Retroviruses 1998; 14:591-597. 50. Dreyer K, Kallas EG, Planelles V, Montefioπ D, McDermott MP, Hasan MS. Primary isolate neutralization by HIV type l-mfected patient sera m the era of highly active antiretroviral therapy. AIDS Research and Human Retroviruses 1999; 15:1563-1571. 51. Allaway GP, Litwm VM, Maddon PJ. Progenies Pharmaceuticals, Inc. Methods for using resonance energy transfer-based assay of HIV-1 envelope glycoprotem-mediated membrane fusion, and kits for practicing same. International Filing Date June 7, 1996. International Patent Application No. PCT/US96/09894. 1996; 52. Chou TC . The median effect principle and the combination index for quantitation of synergism and antagonism. Synergism and Antagonism m Chemotherapy 1991; 61-102. 53. Chou TC, Talalay P. Quantitative analysis of dose- effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances m Enzyme Regulation 1984; 22:27-55. 54. Dragic T., Litwm V., Allaway GP . et al . HIV-1 entry mto CD4+ cells is mediated by the chemokme receptor CC-CKR-5. Nature 1996; 381:667. 55. Donzella GA, Schols D, Lm SW et al . AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 coreceptor. Nature Medicine 1998; 4:72-77. 56. Johnson VA, Merrill DP, Videler JA et al . Two-drug combinations of zidovudme, didanosme, and recombmant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. Journal of Infectious Diseases 1991; 164:646-655. 57. Merrill DP, Manion DJ, Chou TC, Hirsch MS. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir m vitro. Journal of Infectious Diseases 1997; 176:265- 268.

Claims: What is claimed: 1. A composition which comprises an admixture of two compounds, wherem one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell and the other compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate, wherem the relative mass ratio of the compounds m the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. 2. The composition of claim 1, wherem the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a CD4 -based protein. 3. The composition of claim 2, wherem the CD4 -based protein is a CD4- lmmunoglobulm fusion protein. The composition of claim 3, where the CD4- lmmunoglobulm fusion protein is CD4-IgG2, wherem the CD4-IgG2 comprises two heavy chains and two lights chains, wherem the heavy chains are encoded by an expression vector designated CD4-IgG2HC-pRcCMV (ATCC Accession No. 75193) and the light chains are encoded by an expression vector designated CD4-kLC-pRcCMV (ATCC Accession No. 75194) . 5. The composition of claim 1, wherein the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a protein, the amino acid sequence of which comprises that of a protein found in HIV-1 as an envelope glycoprotein. 6. The composition of claim 5, wherein the protein binds to an epitope of CD4 on the surface of the CD4+ cell. 7. The composition of claim 6, wherein the envelope glycoprotein is selected from the group consisting of gpl20, gpl60, and gpl40. 8. The composition of claim 1, wherein the compound which retards the attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is an antibody or portion of an antibody. 9. The composition of claim 8, wherein the antibody is a monoclonal antibody. 10. The composition of claim 9, wherein the monoclonal antibody is a human, humanized or chimeric antibody. 11. The composition of claim 8, wherein the portion of the antibody is a Fab fragment of the antibody. 12. The composition of claim 8, wherem the portion of the antibody comprises the variable domain of the antibody. 13. The composition of claim 8, wherein the portion of the antibody comprises a CDR portion of the antibody. 14. The composition of claim 9, wherem the monoclonal antibody is an IgG, IgM, IgD, IgA, or IgE monoclonal antibody. 15. The composition of claim 9, wherein the monoclonal antibody binds to an HIV-1 envelope glycoprotein. 16. The composition of claim 15, wherein the HIV-1 envelope glycoprotein is selected from the group consisting of gpl20 and gpl60. 17. The composition of claim 16, wherem HIV-1 envelope glycoprotein is gpl20 and the monoclonal antibody which binds to gpl20 is IgGlbl2 or F105. 18. The composition of claim 8, wherein the antibody binds to an epitope of CD4 on the surface of the CD4+ cell. 19. The composition of claim 1, where the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a peptide. 20. The composition of claim 1, wherein the compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4+ cell is a nonpeptidyl agent. 21. The composition of claim 1, wherem the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is an antibody. 22. The composition of claim 21, wherem the antibody is a monoclonal antibody. 23. The composition of claim 1, wherein the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a peptide. 24. The composition of claim 1, wherein the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a fusion protein which comprises a peptide selected from the group consisting of T-20 (SEQ ID NO: 1), DP107 (SEQ ID NO: 2), N34 (SEQ ID NO: 3), C28 (SEQ ID NO: 4), and N34 (L6) C28 (SEQ ID NO: 5). 25. The composition of claim 23, wherem the peptide is selected from the group consisting of T-20 (SEQ ID NO: 1) , DP107 (SEQ ID NO: 2) , N34 (SEQ ID NO: 3) , C28 (SEQ ID NO: 4), and N34 (L6 ) C28 (SEQ ID NO: 5). 26. The composition of claim 23, wherem the peptide is T- 20 (SEQ ID NO: 1) . 27. The composition of claim 1, wherem the compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate is a non-peptidyl agent. 28. The composition of claim 1, wherein the relative mass ratio of each such compound in the admixture ranges from about 25:1 to about 1:1. 29. The composition of claim 28, wherein the mass ratio is about 25:1 30. The composition of claim 28, wherem the mass ratio is about 5:1. 31. The composition of claim 28, wherem the mass ratio is about 1:1. 32. The composition of claim 1, wherem the composition is admixed with a carrier. 33. The composition of claim 32, wherem the carrier is an aerosol, intravenous, oral or topical carrier. 34. A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of claim 1 effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell. 35. The method of claim 34, wherem the CD4+ cell is present m a subject and the contacting is effected by administering the composition to the subject. 36. The method of claim 33, wherem the effective amount of the composition comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight of the subject . 37. A method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of a compound which retards attachment of HIV-1 to the CD4+ cell by retarding binding of HIV-1 gpl20 envelope glycoprotein to CD4 on the surface of the CD4 + cell effective to inhibit HIV-1 infection of the CD4+ cell and an amount of a compound which retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate so as to thereby inhibit HIV-1 infection of the CD4+ cell. 38. The method of claim 37, wherem the CD4+ cell is present m a subject and the contacting is effected by administering the compounds to the subject. 39. The method of claim 38, wherein the compounds are administered to the subject simultaneously. 40. The method of claim 38, wherem the compounds are administered to the subject at different times. 41. The method of claim 38, wherem the compounds are administered to the subject by different routes of administration.

Inventors: MADDON PAUL J, OLSON WILLIAM C, MADDON, PAUL, J., OLSON, WILLIAM, C.
Applicants: PROGENICS PHARM INC, PROGENICS PHARMACEUTICALS, INC.
Application year: 2001
Main classification: C12P21
IPC codes: A61K38, C07K14